All In Biotech

BLA 761107 · Novimmune S.A.

Gamifant

Emapalumab-Lzsg · Injection · Interferon gamma Blocker

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 20, 2018

Approved uses

2

Original approval plus efficacy supplements

Registered trials

29

8 Phase 3, 11 recruiting

FAERS reports

237

209 serious, 106 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 26, 2026.

GAMIFANT is indicated for the treatment of: adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. adult and pediatric patients with HLH/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. GAMIFANT is an interferon gamma (IFNγ) neutralizing antibody indicated for the treatment of: adult and pediatric patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. ( 1 ) adult and pediatric patients with HLH/macrophage activation syndrome (MAS) in known or suspected Still’s disease, including systemic Juvenile Idiopathic Arthritis (sJIA), with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. ( 1 )

Mechanism: Emapalumab-lzsg is a monoclonal antibody that binds to and neutralizes interferon gamma (IFNγ). Nonclinical data suggest that IFNγ plays a pivotal role in the pathogenesis of HLH by being hypersecreted.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 27, 2025 Supplement 18 · Efficacy · priority review OrphanLetterLabel
  • Nov 20, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLetterLabelReview
3 products under this application
  • GAMIFANT · EMAPALUMAB-LZSG 100MG/20ML · INJECTABLE, INJECTION · Prescription
  • GAMIFANT · EMAPALUMAB-LZSG 10MG/2ML · INJECTABLE, INJECTION · Prescription
  • GAMIFANT · EMAPALUMAB-LZSG 50MG/10ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Emapalumab" as an intervention, any sponsor and status, largest first.

All 29 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use94
  • haemophagocytic lymphohistiocytosis72
  • condition aggravated60
  • drug ineffective32
  • death29
  • septic shock21
  • epstein-barr virus infection14
  • multiple organ dysfunction syndrome14
  • adenovirus infection13
  • hypertension13
  • pyrexia13
  • serum ferritin increased12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201917
202015
202112
202218
202318
202431
202562
202664

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Gamifant (Emapalumab-Lzsg) · HCPCS J9210

2024 spending

$7.0M

Beneficiaries

n/a

59 claims

Per beneficiary

n/a

2024 ASP limit $371.31 per unit

View as table
YearSpending
2020$0
2021$409,090
2022$0
2023$0
2024$7,028,970

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: Novimmune S.A.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.